This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Cetilistat
- DrugBank Accession Number
- DB06586
- Background
Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Cetilistat (DB06586)
- Weight
- Average: 401.5821
Monoisotopic: 401.292994119 - Chemical Formula
- C25H39NO3
- Synonyms
- Cetilistat
- External IDs
- ATL-962
Pharmacology
- Indication
Investigated for use/treatment in obesity.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Cetilistat is a gastrointestinal lipase inhibitor that blocks fat digestion and absorption, leading to reduced energy intake, and thus weight loss. It is distinct from most other anti-obesity agents as it does not act on the brain to reduce appetite, but acts peripherally. The compound remains in the gastrointestinal tract with no significant absorption into the body.
Target Actions Organism UPancreatic triacylglycerol lipase Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzoxazines. These are organic compounds containing a benzene fused to an oxazine ring (a six-membered aliphatic ring with four carbon atoms, one oxygen atom, and one nitrogen atom).
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzoxazines
- Sub Class
- Not Available
- Direct Parent
- Benzoxazines
- Alternative Parents
- Alkyl aryl ethers / Benzenoids / Heteroaromatic compounds / Lactones / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
- Substituents
- Alkyl aryl ether / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Benzoxazine / Ether / Heteroaromatic compound / Hydrocarbon derivative / Lactone / Organic nitrogen compound
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- LC5G1JUA39
- CAS number
- 282526-98-1
- InChI Key
- MVCQKIKWYUURMU-UHFFFAOYSA-N
- InChI
- InChI=1S/C25H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-28-25-26-23-18-17-21(2)20-22(23)24(27)29-25/h17-18,20H,3-16,19H2,1-2H3
- IUPAC Name
- 2-(hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one
- SMILES
- CCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C)C=C2)C(=O)O1
References
- General References
- Padwal R: Cetilistat, a new lipase inhibitor for the treatment of obesity. Curr Opin Investig Drugs. 2008 Apr;9(4):414-21. [Article]
- External Links
- PubChem Compound
- 9952916
- ChemSpider
- 8128526
- ChEBI
- 134721
- ChEMBL
- CHEMBL2103825
- ZINC
- ZINC000014128264
- Wikipedia
- Cetilistat
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Diabetes Mellitus, Noninsulin Dependent / Obesity 1 1 Completed Treatment Obesity 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.25e-05 mg/mL ALOGPS logP 8.64 ALOGPS logP 9.26 Chemaxon logS -7.5 ALOGPS pKa (Strongest Basic) -4.4 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 47.89 Å2 Chemaxon Rotatable Bond Count 16 Chemaxon Refractivity 121.46 m3·mol-1 Chemaxon Polarizability 51.21 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9875 Caco-2 permeable + 0.5425 P-glycoprotein substrate Non-substrate 0.573 P-glycoprotein inhibitor I Non-inhibitor 0.7204 P-glycoprotein inhibitor II Non-inhibitor 0.9269 Renal organic cation transporter Non-inhibitor 0.8324 CYP450 2C9 substrate Non-substrate 0.8426 CYP450 2D6 substrate Non-substrate 0.7453 CYP450 3A4 substrate Substrate 0.5619 CYP450 1A2 substrate Inhibitor 0.7619 CYP450 2C9 inhibitor Non-inhibitor 0.663 CYP450 2D6 inhibitor Non-inhibitor 0.9101 CYP450 2C19 inhibitor Inhibitor 0.6868 CYP450 3A4 inhibitor Non-inhibitor 0.8018 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.5808 Ames test Non AMES toxic 0.6672 Carcinogenicity Non-carcinogens 0.9307 Biodegradation Not ready biodegradable 0.9914 Rat acute toxicity 2.2855 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8825 hERG inhibition (predictor II) Non-inhibitor 0.8668
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Triglyceride lipase activity
- Specific Function
- Not Available
- Gene Name
- PNLIP
- Uniprot ID
- P16233
- Uniprot Name
- Pancreatic triacylglycerol lipase
- Molecular Weight
- 51156.48 Da
References
- Yamada Y, Kato T, Ogino H, Ashina S, Kato K: Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats. Horm Metab Res. 2008 Aug;40(8):539-43. doi: 10.1055/s-2008-1076699. Epub 2008 May 21. [Article]
Drug created at March 19, 2008 16:38 / Updated at February 21, 2021 18:52